Diabetes Clinical Trials in Dallas, TX

53 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	<1 mi
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes	Phase 3	Novo Nordisk A/S	<1 mi
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes	N/A	Endogenex, Inc.	<1 mi
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Phase 3	Eli Lilly and Company	<1 mi
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight	Phase 3	Eli Lilly and Company	<1 mi
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	Phase 3	Boehringer Ingelheim	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight	Phase 3	Eli Lilly and Company	<1 mi
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes	Phase 2	Zucara Therapeutics Inc.	<1 mi
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin	Phase 2	Eli Lilly and Company	<1 mi
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes	Phase 3	vTv Therapeutics	<1 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
Assessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions	N/A	University of Texas Southwestern Medical Center	<1 mi
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)	Phase 1/2	COUR Pharmaceutical Development Company, Inc.	<1 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	Phase 3	Eli Lilly and Company	<1 mi
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes	Phase 2	Hoffmann-La Roche	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma	Phase 2	Children's Oncology Group	<1 mi
TrialNet Pathway to Prevention of T1D	—	University of South Florida	<1 mi
Non-Invasive Testing to Evaluate Wound Healing in Diabetes	—	University of Texas Southwestern Medical Center	<1 mi
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial	N/A	Sonavex, Inc.	<1 mi
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)	Phase 2	Sanofi	<1 mi
Registry for Stage 2 Type 1 Diabetes	—	Sanofi	<1 mi
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers	N/A	Piomic Medical	<1 mi
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)	Phase 3	Eli Lilly and Company	<1 mi
SPYRAL GEMINI Pilot Study	N/A	Medtronic Vascular	<1 mi
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes	Phase 3	Vertex Pharmaceuticals Incorporated	<1 mi
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus	Phase 2	Hanmi Pharmaceutical Company Limited	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin	Phase 3	Eli Lilly and Company	<1 mi
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs	N/A	New Horizon Medical Solutions	<1 mi
Bionic Pancreas in CFRD	Phase 3	Jaeb Center for Health Research	<1 mi
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)	Phase 2	Sparrow Pharmaceuticals	<1 mi
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide	Phase 3	Novo Nordisk A/S	<1 mi
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)	Phase 3	Viking Therapeutics, Inc.	<1 mi
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	Phase 2	Eli Lilly and Company	<1 mi
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes	Phase 1	Eli Lilly and Company	<1 mi
Polypill for Prevention of Cardiomyopathy	Phase 1/2	University of Texas Southwestern Medical Center	<1 mi
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study	N/A	University of Texas Southwestern Medical Center	<1 mi
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease	Phase 3	Alessandro Doria	<1 mi
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes	Phase 4	VA Office of Research and Development	<1 mi
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes	N/A	University of Texas Southwestern Medical Center	<1 mi
Tailored Exercise Training Study Among Adults With HFpEF	Phase 2/3	University of Texas Southwestern Medical Center	<1 mi
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus	Phase 2	Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	12 mi
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	Phase 2	Eli Lilly and Company	12 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	12 mi
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes	Phase 3	Kailera	13 mi
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes	Phase 3	Kailera	13 mi
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.	Phase 4	Royal Biologics	13 mi
Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone	N/A	Capsicure, LLC	14 mi
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting	—	Bayer	18 mi
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes	Phase 2	SAb Biotherapeutics, Inc.	31 mi
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes	N/A	Medtronic Diabetes	31 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.